Research presented at the 2018 ASH Annual Meeting provided insights into the role of factor VIII as a therapeutic agent for severe hemophilia A.
Clot waveform analysis of the Clauss fibrinogen assay may allow classification of fibrinogen disorders without measuring fibrinogen antigen levels.
Andexxa was initially granted accelerated approval in May 2018 for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation was needed due to life-threatening or uncontrolled bleeding.
The indication has been changed from "control and prevention of bleeding episodes" to "on-demand treatment and control of bleeding episodes" in adults and children with hemophilia A.
Residual plasma levels of clotting factor XIII or factor IX accounted for around 70% of bleeding phenotype in patients with clinically severe hemophilia.